医薬品リファレンス
Lorlatinib
Lorlatinib is a medicine in the class oncology. It is used for lung cancer.
- 薬効分類: Oncology
- 効能・効果: lung cancer
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01ED05
- 一般的な剤形
- 錠剤
- 一般的な規格
- 25 mg, 100 mg
- 既知の相互作用
- 354 (併用禁忌: 18 · 重大: 101 · 中等度: 209 · 軽度: 26)
- 商品名
- 5
- 国・市場
- 4
何に使われるか
作用のしくみ
ALK/ROS1 tyrosine kinase inhibitor, ALK and ROS1 kinases promote tumor progression in ALK/ROS1 positive lung cancer; lorlatinib binds to and inhibits both kinases, which leads to a disruption of the ALK- and ROS1-mediated signaling; this disruption can subsequently inhibit tumor cell growth in ALK- and ROS1-overexpressing tumor cells
成人の通常用量（添付文書の要約）
Non-small Cell Lung Cancer: 100 mg PO qDay with or without food, Continue until disease progression or unacceptable toxicity
妊娠と授乳
- 妊娠
- Unsafe No available data on use in pregnant women, Based on findings from animal studies and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman
- 授乳
- Unsafe Because of potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment and for 7 days after final dose
報告されている副作用
- Hypercholesterolemia
- Edema
- Hyperglycemia
- Anemia
- Peripheral neuropathy
- Increased ALT & AST
注意が必要な方
- ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days; median time to recovery for Grade ≥3 was 18 days and for Grade 2 was 7 days
- A broad spectrum of CNS effects may occur, These include seizures, psychotic effects and changes in cognitive function, mood (including suicidal ideation), speech, mental status, and sleep
- Avoid coadministration of Fluconazole may increase lorlatinib plasma concentrations and risk of adverse reactions
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (354)
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
- Lonafarnib + Lorlatinib Contraindicated
- Lorlatinib + Lumacaftor / ivacaftor Contraindicated
- Lorlatinib + Mitotane Contraindicated
- Lorlatinib + Pentobarbital Contraindicated
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Lorlatinibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Lorlatinib used for?
Lorlatinib is a medicine in the class oncology. It is used for Lung cancer.
What side effects have been reported with Lorlatinib?
Hypercholesterolemia, Edema, Hyperglycemia, Anemia, Peripheral neuropathy, Increased ALT & AST.
Can Lorlatinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No available data on use in pregnant women, Based on findings from animal studies and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman Breastfeeding: Unsafe. Because of potential for serious adverse reactions in breastfed infants, instruct women not to breastfeed during treatment and for 7 days after final dose
What does Lorlatinib interact with?
MediHelp lists 354 known interactions for Lorlatinib. Contraindicated: 18 · Major: 101 · Moderate: 209 · Minor: 26. The most serious include Amobarbital, Apalutamide, Butabarbital.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
